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Abstract
Viruses are highly e cient vectors that have been used for vaccination and gene therapy
applications. However, their complexity renders downstream process particularly challenging
since devices and strategies especially designed for virus purification are still lacking or need
further optimization. After an introduction to the challenges of virus purification and the
current strategies being employed, this dissertation presents the study of three di erent stages
of the downstream process: clarification, ultrafiltration and chromatography.
A novel clarification procedure based on diatomaceous earth was evaluated. Small-scale
batch incubations led to the identification of Divergan RS – a synthetic non-charged material –
as the most promising candidate for integration in a scalable filtration set-up.
Ultrafiltration was addressed with the evaluation of cassette and hollow fiber modules.
The results obtained show that cassette module with cut-o s in the 500 kDa range and highly
hydrophilic materials enable complete recovery of infective Adenovirus while reducing process
time in half when compared with the best hollow fibers. Despite the encouraging results with
Adenovirus, the experiments using Retrovirus resulted in low yields and possible optimization
strategies were identified.
Membrane technology was also evaluated as an alternative to the packed-bed chromatog-
raphy columns. By using a scale-down 96-well device, the impact of ligand density, membrane
structure and feed conductivity were evaluated for the purification of Adenovirus by ion ex-
change chromatography. The hydrogel-grafted membrane with ligand density of 2.4 µmol cm-2
operated in bind/elute mode shown the best compromise between yield and purity.
Overall, this thesis contributed to the advancement of virus purification field by exploiting
innovative technologies.
Keywords: virus purification; clarification; ultrafiltrattion; membrane chromatography;
biopharmaceuticals; innovative technologies.
ix
x
Resumo
Os vírus são vectores altamente eficientes que tem sido aplicados para vacinação e terapia
génica. Contudo, a sua complexidade torna o processo de purificação particularmente de-
safiante uma vez que materiais e estratégias desenhadas especificamente para purificação de
vírus são inexistentes ou precisam de ser optimizados. Após uma introdução sobre os desafios
relativos à purificação de vírus e estratégias atualmente usadas, é apresentado o estudo de
três etapas diferentes do processo de purificação: clarificação, ultrafiltração e cromatografia.
Foi estudado um inovador processo de clarificação que usa terras de diatomáceas. Os
ensaios em pequena escala identificaram Divergan RS – um material sintético não carregado –
como o candidato mais promissor para a integração no passo de clarificação.
Relativamente à ultrafiltração, foram testados vários módulos de cassete e de fibras ocas.
Os resultados obtidos indicam que os módulos de cassete com um cut-o  próximo de 500 kDa
e material altamente hidrofílico permitem recuperar 100 % dos Adenovírus infecciosos e ao
mesmo tempo reduzir o tempo de processamento para metade relativamente aos módulos
de fibras ocas. Apesar dos resultados positivos obtidos com Adenovírus, os ensaios com
Retrovírus resultaram em baixos rendimentos e as possíveis causas foram identificadas.
A tecnologia de membrana foi estudada como alternativa à de cromatografia de leito com-
pactado. Através um dispositivo de 96 poços, o impacto da densidade de ligando, da estrutura
da membrana e da condutividade da carga foram avaliados na purificação de Adenovírus por
cromatografia de troca iónica. A membrana modificada com hidrogel e uma densidade de
ligando de 2.4 µmol cm-2 resultou no melhor compromisso entre rendimento e pureza.
Na globalidade, esta tese contribuiu para o avanço na área da purificação de vírus através
do estudo de tecnologias inovadoras.
Palavras-chave: purificação de vírus; clarificação, ultrafiltração; cromatografia de mem-
brana; biofármacos; tecnologias inovadoras.
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Introduction

1
Purification of complex
biopharmaceuticals
1.1 Complex biopharmaceuticals
Biopharmaceuticals are structured and highly specific biomolecules capable of targeting
unmet medical needs where other drugs have failed. The success of these novel bio-based
pharmaceuticals has been reshaping medical therapies over the past decades [1]. Nowadays
there are numerous biopharmaceuticals (both approved and under development) with a wide
range of sizes, levels of complexity and medical indications [2,3]. Some examples of approved
biotherapeutics are the Factor VIII (blood factor), tissue plasminogen activator (antico-
agulant/thrombolytic), insulin and insulin-derived products, erythropoietins, interferon-–,
pegaptanib (nucleic acid-based anti-angiogenic medicine), monoclonal antibodies (mAbs),
human papillomavirus (HPV) virus-like particle (VLP) vaccine, inactivated influenza virus
vaccines and adeno-associated viral (AAV) gene therapy vector (Glybera®) [2,4].
Among the above-referred biomolecules virus-based biopharmaceuticals hold a great
promise to redefine modern medicine in di erent fields such as vaccination [5], gene therapy [4]
and cancer treatment [6]. However these biopharmaceuticals represent also a series of the
challenges both product- and process-wise since their are not as well studied and developed
as other less complex biopharmaceuticals already established.
1.1.1 The challenges of complex biopharmaceuticals
Virus and virus-like particle are considerably larger than an insulin protein or a mAb
and their size can range from 20 nm (parvovius) to 300 nm (Measles and Mumps virus),
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with di erent possible morphologies (i. e. the rod-shape of Baculovirus) [7,8]. The highly
repetitive tri-dimensional structure is fundamental for immunization in the case of vaccines.
Additionally, post-translational modifications, like glycosylation, impact the immunogenicity
and antigenicity of the vaccine [9,10]. For gene therapy applications the vector quality is
crucial [11].
As a result of this complexity, animal cell lines have to be used often for production of
these virus-based biopharmaceuticals. The new virus vaccines are now produced in cell-based
systems. The traditional production with fertilized eggs has several drawbacks since it is a
work-intensive process, is dependent on egg supply, is not fast enough in the case of a global
pandemics and might cause anaphylactic reactions due to egg’s proteins [1,7,12]. Vaccines
recently developed and under development make use of continuous mammalian cell lines such
as the African green monkey kidney (VERO) cells [13,14], the human lung fibroblast (MRC-
5) cells [15], Madin-Darby Canine Kidney (MDCK) cells [16], human embryonic retina-derived
PER.C6®cells (Crucell) [17–19] and human embryonic kidney (HEK) 293 [19,20].
The VLP-based vaccines might be produced by a wide range of hosts from mammalian
cell lines to transgenic plants, however only VLPs produced in yeast and animal cell lines were
approved by regulatory authorities [5,8]. The recombinant hepatitis B vaccines are produced
almost exclusively in yeast systems (Saccharomyces cerevisiae, Pichia pastoris and Hansenula
polymorpha) with the exception of chinese hamster ovary (CHO) cells, which is the only
mammalian cell line used. S. cerevisiae is also used for production of the Merck & Co’s
HPV-VLP [21] whereas the GSK’s HPV-VLP is produced with the baculovirus-insect cell (B-
IC) system [22]. These expression systems seem to have a favorable compromise between high
productivity/yield and capability to perform post-translational modifications [5].
Contrarily to VLPs, the gene therapy vectors are less flexible in terms of production
system and the system chosen is dependent on the virus used. Ad-based vectors are produced
in a complementing cell line (see Section 1.1.2), such as the 293 and the PER.C6® cell
lines [19,23]. In the case of AVV vectors, like UniQure’s Glybera® – recently approved by
EMA –, these can be produced in mammalian cell lines as well as with the B-IC system [24,25].
The current retrovirus production systems rely on genetically engineered virus packaging cell
lines (see Section 1.1.3), usually human-derived cell lines [26,27].
As biopharmaceuticals are intended for therapeutic human use there are stringent guide-
lines put in place by the regulatory agencies (e. g. EMA or FDA). The Table 1.1 reports the
quality attributes evaluated by the regulatory authorities [28,29].
The analyticals for virus-based biopharmaceuticals must be highly specific and robust,
however often new analytical assays must be developed and validated, specially for innovative
therapeutic biomolecules. Additionally, the lack of well-characterized and accepted standards
adds up to the challenges of developing new analytical assays for such specific products [1,31].
The final goal is to obtain a biopharmaceutical of high purity (process-related impurities,
like HCP and DNA, within regulatory specifications), high potency (highest concentration
feasible of the relevant active component) and high quality (low concentration of product-
derived impurities relatively to the desired product, e. i. virus capsid proteins or non
functional virions).
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Table 1.1: Specifications for biotechnological products [28–30].
Attribute Specification
Appearance and
description
Color
Physical state
Clarity/turbidity
(Qualitative statement)
Identity
Multiple tests might be required:
Physicochemical
Biological
immunichemical
(Highly specific but
might be qualitative)
Purity
Product-related
impurities
Degradated product
Truncated forms
Molecular variants
Aggregates
Process-related
impurities
Host cell protein (HCP)
Host cell DNA
Media components/ancillaries
Enzymes/chemicals
Leachables
Potency Cell-based test orAnimal-based test
Quantity Protein mass orPotency (if applicable)
Safety
Sterility
Adventitious virus
Endotoxins/Pyrogens
Mycoplasma
General pHOsmolarity
Two highly relevant representatives of these virus-based biopharmaceuticals are aden-
ovirus and retrovirus.
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1.1.2 The Adenovirus - a stable proteic capsid particle
The Adenoviridae family is composed of over 100 virus, 57 serotypes of which are capable
of infecting humans [32].
The adenovirus serotype 5 (Ad5) was the first adenovirus discovered when its icosahedral
shape was reveled by Horne in 1959 [33]. Since then it has been extensively studied, used
as virus model and nowadays is widely characterized. The Ad5 is a nonenveloped double-
stranded DNA virus with a molecular weight of 150-170 MDa (90-100 nm in diameter) [32,34,35],
has a pI of approximately 4.5 and thus is negatively charged at physiological pH [36]. The
virus is composed of 11 di erent proteins (Figure 1.1), 7 are the structural proteins (II, III,
IIIa, IV, VI, VIII and IX) which compose the icosahedral virus capsids and the remaining 4
proteins (V, VII, mu and terminal protein) are packed inside the capsid together with the
virus DNA to form the core [32,37,38].
The virus capsid is composed of twelve hexon trimers (polypeptide II - 107.9 kDa for Ad5)
in each of the 20 facets and twelve pentons in each of the twelve vertices (Figure 1.1). Each
penton is a protein composed of one pentamer, the penton base (polypeptide III - 63.3 kDa
for Ad5), and one trimer, the fiber (polypeptide IV - 61.6 kDa for Ad5) which is responsible
for the adsorption to the cell surface via the CAR (Coxsackie/Adenovirus receptor) and
–v-integrins. The remaining (minor) coat proteins are involved in virus stability, correct
assemble and disassemble of the virion [32,38,39].
V
terminal
VII
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dsDNA
VIII
VI
fiber (IV)
IX
IIIa
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penton base (III)
Figure 1.1: Structure of the Adenovirus by cross-section representation. The coat proteins are listed
on the right side and the core proteins and DNA are on the left side.
The application of Ad5 goes beyond fundamental research and its use as biotechnology
product is very significant, either as gene therapy vector [40], oncolytic virus [41] or recombinant
vaccines [42,43]. The best know examples are the use of recombinant p53-Ad5 approved in
China for cancer therapy [44,45] and the Merck & Co’s candidate HIV Ad5-based vaccine
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(although clinical tests failed for Ad5-based vaccine, currently di erent, rarer Ad serotypes
are being evaluated) [46,47].
However to use Ad-based therapies safely, these virus are genetically modified to render
replication-incompetent vectors (or conditionally replication-competent virus for oncolytic
therapy). To accomplish this several genes of the Ad5 genome were removed or mutated.
Initially the genes targeted were involved in viral DNA transcription, inhibition of cell apop-
tosis, avoiding host immune response and viral DNA replication [32]. More recently, helper-
dependent Ad (also named gutless or high-capacity) were developed. Since these vectors have
no viral DNA, a helper virus has to be used to provide all structural proteins [23,32,48,49].
For the production of replication-incompetent adenoviral vectors trans-complementing
cell lines must be used in order to provide the deleted functions. Several cell lines have been
used for Ad production, with the 293 and the PER.C6® being the most used. Since the Ad-
producing cell lines can adapted to grow in suspension, stirred-tank bioreactors have been
used with or without the aid of microcarriers [19,23].
1.1.3 The Retrovirus - a labile enveloped particle
The Retroviridae is a family of viruses characterized by their RNA genome and its retro-
transcription into DNA prior to protein synthesis. Notable species of this family include
the murine leukemia virus (MLV), belonging to the gamma-retrovirus genus (herein referred
to as retrovirus (RV)) and the human immunodeficiency virus (HIV) which belongs to the
Lentivirus genus [50]. The RV is an enveloped, spherical, slightly pleomorphic particle with a
diameter of 100-120 nm (Figure 1.2). The virion structure is divided in three major parts, the
RT
PR
RNA
IN
CA
NC
MA
SU
Env
Gag
TM
Lipid
bilayer
Figure 1.2: Structure of the Retovirus by cross-section representation.
envelope, the proteic capsid and the viral genome. The envelope that covers the the proteic
capsid is composed by a bi-lipidic layer and 100-300 Env glycoproteins (69.8 kDa) consisting
of transmembrane (TM, 19.9 kDa) and surface (SU, 47.9 kDa) subunits. The SU subunit
interacts with the cell membrane receptors to promote the fusion of the envelope with the cell
membrane during the infection process. Given its function, the Env protein (and the virus
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envelope) is of great relevance of highly infective retroviral preparations. The Gag protein
(60.7 kDa) interacts both with the Env proteins by its N-terminal matrix domain (MA) and
the inner space of the virus capsid with through its C-terminal nucleocapsid (NC) domain.
Inside this proteic structure, besides the ssRNA molecule, there are also the PR (responsible
from virus’ protein cleavages during assembling, budding and maturation), the RT (which
does the reverse-transcription of the viral RNA) and the IN (responsible for integrating the
pro-viral DNA) proteins [51,52].
Retroviral vectors are highly advantageous for gene therapy due to their high transduction
e ciency of replicating cells, low immunogenicity and ability to integrate the proviral cDNA
(with the therapeutic gene) into the host genome, rendering a long-term e ect [48]. Moreover,
RV are the second most used gene therapy vector in clinical trials worldwide (the first being
adenovirus) [53].
Since retrovirus have a modular structure they can be pseudotyped, i. e. the env region
of the genome can be replaced by the env region of another, more favorable, retrovirus.
The possibility to engineer the vector allowed to change, restrict ou broaden vector tropism
and to modulate its immunogenicity. Among several Env proteins used, the MLV-based
retrovirus pseudotyped with gibbon ape leukemia virus (GaLV) Env has been one of the
most studied [26,27].
As earlier described for Ad5, also retroviral vectors being developed for human therapeutic
purposes must be replication-incompetent. This is accomplished by providing the transgene of
interest together with the packing signal in a di erent transcriptional unit(s) than the packing
functions (env and gag-pro-pol). Current RV generations have three di erent transcriptional
units (transgene, gag-pro-pol and env) with reduced sequence homology, thus reducing greatly
the frequency of replication-competent RVs [26,27].
For retrovirus production the packing functions (i. e. structural proteins) can be supplied
either by a plasmid transfection (transient production) or by a packing cell line engineered to
express constitutively those functions (stable production). While transient production is only
suitable for small scale research purposes, the stable production includes the long process of
developing a high titer packing cell line but yields a continuous low-variability production
suitable for clinical lots. Currently, human cell lines, namely HEK-derived, are preferred to
the murine cell lines for the development of retrovirus-producing cells [26,27,54].
The RV-packing cells are generally cultured in static systems due to their anchorage-
dependent feature. High capacity static system such as the Cell Factory® have been reported
for clinical production of RV under current good manufacturing practices (cGMP) [55–57].
These kind of strategies enable a limited but rapid and reliable scale-up and might provide
enough material for pre-clinical and early clinical phases.
1.2 Current scalable DSP strategies
The biopharmaceutical process is no longer seen as the sum of upstream with downstream
processes and there is a e ort to integrate and design together production and purification.
Despite this, the downstream process is still crucial to obtain the final intended product; also
the substantial developments achieved in the upstream process were not matched by small
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improvements in the downstream. Furthermore, the cost of purification can go from 50 % up
to 70 % of the total process [58,59]. Meaning that careful choice of operations, materials and
equipment should be made to in order to keep the whole process cost-e ective. Besides cost,
the scalability of the DSP developed is a key issue. Robustness is also a required feature so
that small variations in upstream processing as well as in previous downstream operations
do not impact the whole bioprocess performance and final product quality.
The following section describe the state-of-the-art regarding virus purification including
novel technological advances, emerging industry trends and rational process development
approaches for di erent stages of the DSP train. Some examples are the greater integra-
tion between upstream and downstream, high density cell systems, continuous processing,
scale-down tools closed systems, modulatiry, numbering up instead of scale-up (for niche
biopharmaceuticals) and disposable technologies [60–64].
1.2.1 Harvest
The first steps of the purification train are heavily influenced by the bioreactor bulk fea-
tures, namely cell density, cell viability or if the product is secreted for the culture supernatant
or if the cells have to be lysed.
In cases such as Ad5 production, is usually chosen to recover both the intra- and extra-
cellular virus faction and thus an additional step is performed for virus release [19,23]. The cell
lysis can be performed using di erent methods such as freeze-thaw, detergents, French Press,
homogenizer or sonication [65]. Among these, non-ionic detergents especially Triton™ X-100
have been preferred [18,19,65–67]. Incubating the bulk with detergent is e cient, fast, robust,
easily scalable, cost-e ective and does not require any investment in equipment, however
removal of this additive has to be confirmed.
Although cell lysis enables the recovery of intra-celullar virus it also releases the host
cell DNA and protein which should be removed from the final product. Host cell DNA is of
special concern because it increases substantially bulk viscosity but also due to regulatory
requirements. The DNA acceptable levels set by the regulatory authorities are generally
between 10 ng and 10 pg per dose, depending on type of product, medical indication, pro-
duction host and administration route. Therefore, the majority of scientific manuscripts
published and patents disclosed refer an incubation step with nuclease (e. g. Benzonase®)
either simultaneously with cell lysis or after clarification [18,19,65–68]. For enveloped virus, like
RV or baculovirus, cell lysis is not required since the virus are secreted by the producer cells
– budding process. Therefore, the use of nuclease might be avoided for enveloped virus DSP
due to its high costs [54,69].
Selective precipitation has been suggested as an alternative to nuclease treatment to
remove host cell DNA [17,70–72]. Cationinc detergents (namely domiphen bromide) are able to
precipitate DNA as well as Ad particles (both negatively charged and mildly hydrophobic).
However fine adjustment of precipitant concentration enables up to 90 % DNA removal with
more than 90 % Ad recovery [70]. Selective DNA precipitation has the advantage of being
inexpensive, easily scalable (precipitated DNA can be removed by depth filter) and suitable
for high cell density processes [17,71].
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1.2.2 Clarification
The goal of clarification is to recover and stabilize the product while removing solids,
cells/cell debris and process impurities (DNA and HCP). Centrifugation and membrane fil-
tration are the two common choices for the initial clarification.
Centrifugation is an operation widely used at laboratory scale for research purposes both
to clarify the cell culture fluid (CCF) and to obtain high purity viral preparations (by CsCl
gradient ultracentrifugation). The centrifugal separation is based on the solutes’ di erent
densities meaning that clarification is generally a fast process. However, centrifugation has
several issues like the high maintenance costs, the lack of reliable scale-down model, does not
remove soluble impurities and safety risks must be considered (for instance the Ad5 forms
aerosols) [19,68,73]. Despite the earlier described limitations, continuous flow centrifugation
are quite common in current industrial-scale operations for mAbs clarification where biore-
action yields very high cell density CCFs (107 cell mL-1 and above). However in these cases
the clarification also comprises a depth filter operation to achieve higher removal of soluble
impurities (DNA and HCP) and low turbidity [74–77].
Microfiltration (MF) is an alternative to centrifugation which can be easily scaled up and
implemented in a cGMP setting. Microfiltration membranes have pore sizes in the 0.1–10 µm
range and can be classified as depth filters or "regular" filter depending on whether the solids
are retained throughout filter matrix/medium or only at its surface, respectively. Addition-
ally, depth filter might include filter aids, e. g. diatomaceous earth (DE), to modify its struc-
ture and charge [78]. Depth filters have been used for a wide variety of VLPs and viruses (en-
veloped and non-enveloped) with recovery yields of approximately 90 % [66,67,69,79,80]. Depth
filters are usually preferred for feed streams with high biomass contents, sometimes lysed
CCF, due to their ability to remove solids and impurities by di erent mechanisms (size ex-
clusion, hydrophobic and electrostatic interactions) [81]. Carefull selection of the filter (pore
size, filter material, number and sequence of filter units) and operation parameters (inlet flow
rate, pressure drop, conductivity and pH) must be assessed in order to avoid virus losses
and to allow solids and soluble impurities retention throughout the whole depth of the fil-
ter medium rather than only at the filter surface. Often the trade-o  between feed flow
rate/throughput and filter capacity/impurity removal should be evaluated [77,82].
Membrane microfiltration has also been performed either in normal (dead-end) or tangen-
tial flow filtration (TFF) [79,83]. Microfiltration is usually operated at low pressures, especially
TFF (less than 0.7 bar), and is better suited for low cell density CCFs [74]. However, mem-
brane fouling or shear stress-induced cell lysis can become an issue [84].
More recently, a new microfiltration separation was purposed where a filter aid is mixed
with the CCF instead of being incorporated in the depth filter units [85,86]. The CCF and
filter aid (diatomaceous earth, layered double hydroxides or synthetic materials) are mixed
and fed to a microfilter. This novel filtration would permit an enhanced adsorption during
mixing and the formation of highly porous and highly permeable cake (body feed) supported
by the filter aid, similarly to what is done in the brewing industry where diatomaceous earth
is used to clarify beer [87]. Several patents applications claim that the body feed filtration
(BFF) would avoid membrane fouling, enable lower pressure operation for longer times at
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higher flow rates without compromising impurity removal. One paper recently published [88]
referrers the use of DE for clarification of a poliovirus CCF, however the performance of this
method was not disclosed and its potential remains unexplored.
1.2.3 Concentration
Large-scale process can produce high volumes of CCF (up to 20 kL for mAbs [89]) which
must be concentrated 10–100 times to be further purified by chromatographic steps. Ul-
trafiltration (UF) is a pressure-driven separation which employs anisotropic membranes with
molecular weight cut-o s (MWCO) ranging from 0.5 to 1000 kDa [84]. (The MWCO is defined
by the solutes’ molecular mass which are 90 % retained by the membrane.) These membranes
can be constructed with di erent polymers like regenerated cellulose (RC), polysulfone (PS),
polyethersulfone (PES) and polyvinylidene fluoride (PVDF), although RC and modified RC
displays better trade-o  between low (unspecific) protein binding, mechanical strength and
resistance to cleaning procedures (chemical agents and temperature) [74,90,91]. Ultrafiltration
membrane are generally composed by two main layers, a thick macroporous structure pro-
vides mechanical strength while a thin skin layer is responsible for membrane selectivity and
permeability [74].
Ultrafiltration is usually performed in TFF mode where the cross flow at the membrane
surface creates a "sweeping action" that avoids or lessens concentration polarization and gel
layer formation. UF processes are usually performed at constant transmembrane pressure
(TMP, see equation 2.5, page 20), however constant permeate flux or constant permeate
pressure operation are also feasible [74]. Ultrafiltration has been widely used both in
concentartive mode as well for bu er exchange (diafiltration, DF) step and is present in almost
every virus DSP described in the literature [79,83,92–97] and patents disclosed [18,71,98]. The
membranes used in virus UF have MWCO in the range of 100–750 kDa allowing for high virus
recovery (70–100 %). The TMP generally used is between 0.5 and 1.4 bar but the optimum
cross flow can vary greatly due to di erent structural stability of virus; enveloped virus are
more labile than non-enveloped virus and thus more prone to shear-induced damage [83,97].
The membrane modules might be constructed in di erent arrangements, for example flat
sheet cassette and hollow fibers. However the majority of the reports published referrers the
use of hollow fibers (HF) modules for virus processing [7,99] due to the fact that HF modules
provide wider flow paths resulting in lower shear rates [7,84]. Shear rate is proportional to
the linear velocity of the feed and inversely proportional to the flow channel diameter or
height (see equation 2.9, page 21 for further details). The flow channel geometry influences
the shear rate two ways: firstly, the wider flow channel result in lower linear velocity for the
same volumetric flow rate; and secondly, the wide flow channel results itself in lower shear
rates. Although UF cassettes results in greater shear rates, these modules provide shorter
processing times as the flow channel hydrodynamics are more e ective than HF in avoiding
concentration polarization and gel layer formation [7,84].
Besides UF, rediscovered techniques like aqueous two-phase systems [100,101] and precipi-
tation [102–104] have been suggested for early-stage operations in mAb DSP, however its ap-
plicability and e cacy remains unclear for virus-based biopharmcaeuticals [105].
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1.2.4 Intermediate purification
The purification step(s) employs high resolution unit operations capable of removing
impurities closely related with the product, being chromatography the best example. Purifi-
cation scientists have relied mainly on ion-exchange and size exclusion chromatography to
process virus particles [23,26,92,106], although other techniques like a nity [92,99], hydrophobic
interaction (HIC) [107,108] and multimodal [67] have been suggested.
Ion-exchange (IEX) chromatography is the method of choice for capture step. The virus-
containing feed is loaded in the chromatographic matrix under low or moderate conductivity
and recovered upon a conductivity increase of the mobile phase. The functional groups Q
(quaternary amine) and DEAE (diethylaminoethyl) are common choices for this bind/elute
(or positive) mode chromatography [23,99]. Accurate process development enables highly se-
lective AEX chromatography capable of discriminate between whole virus and virus capsid
proteins [109] or di erent adenovirus serotypes [110,111].
Despite being widely used, packed-bed chromatography has several disadvantages: the
pressure drop is high and increases during operation due to matrix deformation or pore
obstruction; scale-up requires changes in the column geometry making scale-up problematic;
the mass transfer is slow since it is limited by pore di usion; the capacity is limited to the
ligand available at bead surface since the small pores (10–400 µm) will exclude the virus
particles. Additionally, the di usion-limited transport greatly reduces binding capacity at
high flow rates (20–500 column volumes per hour) [112–114].
Membrane chromatography, in which a macroporous membrane serves as support to
bound functional ligands, has the potential to overcome the limitations of the traditional chro-
matography resins [114]. Monoliths – a single polymer block with a network of functionalized
flow paths highly interconnected – have also been suggested as an alternative for packed-bed
chromatography [115]. The nearly-convective mass transport enables operation at flow rates
up to 500 membrane volumes per hour without decreasing binding capacity – reducing pro-
cessing times. The wide porous (up to 3 µm) allow lower pressure drops and compact design
compared with packed-bed chromatography reduce hardware requirements and facility foot-
print. Scale-up is greatly facilitated due to the modular design of chromatography supports.
Since membranes adsorbers are single-use devices, column (re)packing, cleaning and valida-
tions are avoided. The advantages referred above enable savings with the consumables and
labor costs [62,116,117], despite some limitations regarding membrane chromatography. While
multilayer membrane modules mitigated the distorted inlet flow, uneven membrane thick-
ness and uneven pore size of the first membrane adsorbers some issues still remain. The
major drawback of membrane adsorbers is lower binding capacity compared with packed-bed
columns due to the lower surface-to-volume ratio [113,114]. AEX membrane adsorbers were first
developed as flow-though (negative mode) chromatography for polishing step in mAbs DSP
to capture virus, DNA and HCP [118]. However when used for virus purification, the product
recovery (desorption) and removal of closely related species (e. g. DNA) is limited. Consid-
ering these drawbacks optimization of ligand density and membrane surface tri-dimensional
structure were suggested to overcome the referred limitations [119].
Another di erent option to improve chromatography is the use of radial columns, where
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the chromatographic resin is packed in a cylinder form. The advantage of this columns lie in
the radial flow design which enables a small bed length while attaining high column volumes.
This feature results in low and uniform pressure drops across the packed-bed allowing for
increased flowrates (and productivity), small equipment foot-print and linear scale-up since
column geometry is kept [120,121].
Recently, Genzyme and Genentech’s scientists have developed a continuous process for
purification of mAbs and recombinant therapeutic enzymes using HIC and a nity chromatog-
raphy [63,64,122]. In the conventional batch operation the chromatographic matrix is loaded
until product breakthrough is detected at the outlet (i. e. 5 or 10 % of feed concentration).
This means that only a fraction (between 30 and 70 %) of the chromatographic resin capacity
is used because breakthrough happens before the matrix gets fully loaded. In the described
periodic counter-current chromatography (PCC) process the breakthrough e uent is loaded
onto a second column enabling loading the first column until exhaustion (up to static binding
capacity). This strategy enables, reduced bu er consumption, shorter processing times and
better matrix usage (with concurrent investment and facility footprint savings) [63,64].
1.2.5 Polishing
The final step of purification aims to remove small quantities of impurities and to ex-
change the bu er for the final formulation. Ultrafiltration and size exclusion chromatogra-
phy (SEC) have been used for this purpose although ultrafiltration is preferred for large-scale
manufacture [68,71,106] Bu er exchange by size exclusion chromatography is performed in way
such that virus particles are excluded from the resin while smaller size molecules (bu er,
HCP and DNA) and ions are retained [117]. However, due to the di usion-limited fractiona-
tion mechanism and compressible nature of SEC resin, low flow rates have to be used thus
resulting in low productivity. Furthermore, scale up of SEC is limited by technical and eco-
nomic constraints [74,123]. On the other hand, ultrafiltration is easily scalable and allows for
bu er exchange of high volumes. Additionally, some components of formulation bu ers (e.
g. glycerol or trehalose [124,125]) that increase the viscosity can be incorporated in diafiltra-
tion bu ers contrarily to chromatography. However TMP, shear rate, diafiltration number,
MWCO and membrane material must be carefully optimized for optimal product recovery
and short processing time. Hydrophobic interaction chromatography (HIC) was recently sug-
gested to remove trace amounts of HCP and DNA, however the high conductivity required
limits its application to virus sensitive to high conductivity [107,108,126].
1.3 Scope of the thesis
Virus are biopharmaceuticals holding a tremendous potential for vaccine and gene therapy
applications. Despite recent research e orts have targeted purification of complex biological
particles, virus downstream processing is still a challenging field. The product characteristics
– virus lability/stability or large size – limit the unit operations that can be used. Further-
more, the upstream process employed results in closely related impurities that have to be
removed in order to achieve clinical-grade preparations. Purification devices and strategies
13
1. PURIFICATION OF COMPLEX BIOPHARMACEUTICALS 1.3. Scope of the thesis
especially designed for virus purification are lacking or need further optimization; addition-
ally most of the research and development (R&D) has been focused on the chromatographic
step – considered the major bottleneck of the purification train. As a result, the literature
thoroughly evaluating non-chromatographic operations for virus DSP is scarce. This thesis
aims to improve the state-of-the-art virus purification by evaluating essential but less studied
separations – clarification and ultrafiltration – as well as other better characterized DSP steps
– membrane chromatography.
Clarification by depth filter is a technology easily scalable, capable of removing soluble
impurites and suspended solids. However limitations such as low filter capacity and low flow
rates have been identified [77,82]. In Chapter 3 a novel clarification process based on body feed
filtration (or cake filtration) concept was evaluated. For this purpose di erent filter aids (DE
and synthetic polymer; charged and non-charged) were assessed for clarification of an Ad5
bioreactor bulk.
Ultrafiltration is present in all large-volume virus purification schemes. Virus concen-
tration and diafiltration is usually performed using hollow fiber UF modules. Despite its
generalized use, HF are known to be slower and more prone to fouling when compared with
cassette modules. Considering the advantages of cassette UF, a study with R&D UF cassette
prototypes was performed in the first part of Chapter 4. In the second part of the chapter, a
comparative evaluation between commercial HF and late-stage cassette devices is described.
Two di erent virus (Ad5, non-enveloped, and RV, enveloped) were used as models to char-
acterize membrane MWCO and filter material and its impact on virus recovery, impurity
removal and processing time.
Membrane adsorbers have several advantageous features comparing with the traditional
packed-bed column chromatography. However, further improvements are required to increase
the adoption of this technology. The last part of this thesis (Chapter 5) reports the use of a
scale-down tool to evaluate how conductivity of the mobile phase, ligand density and structure
of an IEX membrane a ect a chromatographic purification of Ad5.
Overall, this thesis aims to evaluate the potential of enhanced and innovative technologies
to improve productivity and reduce cost-of-goods in the whole DSP train.
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Materials and Methods
2.1 Cell lines, culture media and virus strains
The 293 cell line (ATCC CRL-1573) was used for adenovirus production as well as infec-
tious virus particles (IP) titration. A recombinant replication-defective adenovirus serotype
5 harboring a transgene for the green fluorescent protein (GFP) were used; the virus stock
was kindly provided by Professor Stefan Kochanek, University of Ulm, Germany. The
recombinant RV was produced in 293-derived cell line gene genetically engineered to provide
constitutively the packing functions required for RV assembly as described elsewhere [127].
The RV produced is derived from the murine leukemia virus (MLV) with the Gibbon ape
leukemia virus (GaLV) ecotropic envelope and harbors a GFP reporter gene. The 293 T cell
line (ATCC CRL-11268) was used for infectious RV titration.
The 293 and 293 T cell lines were grown in cell culture flasks (353112, BD Falcon™, USA)
with Dulbecco’s Modified Eagle Medium (DMEM, 41966-052, Gibco®, UK) supplemented
with 10 % (V/V) Fetal Bovine Serum (FBS, 10270-106, Gibco®, UK). For the 293 Flex GFP
the medium used was DMEM without phenol red (31053-036, Gibco®, UK), supplemented
with 10 % (V/V) FBS and 4 mM L-Glutamine (25030-024, Gibco®, USA). The 293 cells
were grown in a humidified atmosphere of 5 % CO2 at 37¶C, whereas the Flex 293 and
293 T were grown in a 8 % CO2. The cells were routinely propagated twice a week using
0.05 % Trypsin-EDTA (25300-104, Gibco®, UK). The cell concentration and viability were
determined by counting cells on a Fuchs-Rosenthal haemocytometer (Brand, Germany) using
the dye exclusion method with 0.1 % trypan blue (15250-061, Gibco®, UK).
For the suspension culture system (i. e. bioreactor production, see section 2.2.2) the
293 cells adapted to suspension were grown with the commercially available serum-free cul-
ture medium Ex-Cell 293 (14570C, SAFC®, USA) supplemented with 4 mM L-Glutamine
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(25030-024, Gibco®, USA). The cells were routinely propagated twice a week using an inocu-
lum of 0.5◊10+6 cell mL-1. Erlenmeyer shake flasks (431255, CORINING, USA) were used
for suspension cell culture in a humidified atmosphere of 8 % CO2 at 37¶C. Agitation was
provided by orbital shaking at 110 rpm.
2.2 Virus production
2.2.1 Ad5 stock production
For the small scale virus production, ten 175 cm2-cell culture flasks (353112, BD Falcon™,
USA) with 80-90 % confluence were infected with a previously purified and characterized viral
stock using a multiplicity of infection (MOI) of 5.
2.2.1.1 CsCl gradient purification
After 48 h, the infected cells were centifuged at 1 500 g for 5 min, ressuspended in lysis
bu er (10 mM TRIS, pH 8.0, 0.1 % (V/V) Triton X-100) and vigorously shaken. The cel-
lular debris were removed by centrifugation at 1 000 g for 10 min and the virus-containing
supernatant was collected. This fraction was further purified by two rounds of CsCl ultra-
centrifugation (Optima™ LE-80K, SW 41 Ti rotor both BECKMAN COULTER, USA). The
first round consisted in a discontinuous CsCl ultracentrifugation (1.25/1.45 kg/L density) at
151 000 g for 90 min. The visible virus band was extracted and processed by a continuous
CsCl gradient ultracentriguation (1.32 kg/L) at 151 000 g for 18 h. After the second of ul-
tracentrifugation, the virus band collected was purified by SEC (HiPrep™ 26/10 Desalting,
17-5087-01, GE Healthcare Life Sciences, Sweden) in order to change for the formulation
bu er (10 mM TRIS, pH 8.0, 2 mM MgCl2, 0.5 M trehalose). The purified virus stock was
sterilized with 0.2 µm filter (4554, Pall, USA), aliquoted and stored at -80¶C until further
use.
2.2.2 Ad5 bioreactor production
The Ad5 production was performed in a 5-L working volume bioreactor (Sartorius Ste-
dim Biotech, Germany). The dissolved oxygen was controlled at 50 % air saturation by a
N2/O2/air mixture delivered by a sparger. The aeration rate was 0.01 vvm (vessel volumes
per minute). The pH-value was controlled at 7.2±0.05 by aeration with CO2 in the gas mix-
ture and by base addition (1 M NaHCO3). The temperature was controlled at 37¶C using
an external water-filled jacket. Mixing was provided by two 6-segment Ruston impellers with
the agitation rate controlled between 60 and 210 rpm.
The bioreactor inoculum was 0.5◊10+6 cell mL-1, the cell concentration at infection (CCI)
was 1◊10+6 cell mL-1 and a MOI of 5 was used. The bioreactor was harvested 48 hours post
infection (hpi).
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2.2.3 RV production
For RV production twenty 175 cm2-cell culture flasks (353112, BD Falcon™, USA) were
used to expand the 293 Flex GFP cell in the serum-supplement medium. When the cell
confluence reached 80-90 % the medium was replaced by 25 mL of serum-free medium. The
cell culture supernatant was collected 24 h after medium exchange.
2.3 Virus purification
2.3.1 Harvest and Clarification
After Ad5 bioreactor harvest, the cells were lysed by adding Triton X-100 (X100,
SIGMA-ALDRICH®, Switzerland) to a final concentration of 0.1 % (w/w). Simultane-
ously, Benzonase® (101654, Merck Millipore, Germany) was added to a final concentration
of 50 U/mL. The virus-containing bioreactor bulk was incubated at 37¶C for 2 h.
Clarification of Ad5 bulk was performed resourcing to a Sartopore® 2 filter with
0.8 + 0.45 µm pore size (5445306G8--OO, Sartorius, Germany). Before filtration the mod-
ule was primed with three capsule volumes of TRIS bu ered saline, pH 8.0 (TBS; T6664,
SIGMA-ALDRICH®, Switzerland). The virus-containing bulk was loaded to the filter at a
constant flow rare equivalent to 150 LMH using a Tandem 1082 Pump (Sartorius Stedim
Biotech, Germany).
Cell lysis and nuclease incubation was not performed for the RV-containing bulk since the
these enveloped virus were collected in the cell culture medium. The RV-containing super-
natant was clarified using a 0.45 µm vacuum-driven filter (SCHVU05RE, Merck Millipore,
Germany). The filter was conditioned with 500 mL of TBS, pH 8.0 before virus microfiltra-
tion.
2.4 Body feed filtration
For the screening four filter aids were tested:
Celpure® C300 (Advanced Mineral™, USA)
Celpure® C1000 (Advanced Mineral™, USA)
Celite® (World Maetrials, USA)
Divergan® RS (BASF, Germany)
All the filter aids were kindly provided by Dr. Franziska Jonas (Downstream Process
Technologies, Sartorius Stedim Biotech, Germany)
The screening procedure consisted in incubating 10 g of each of the filter aids with 50 mL
of Ad5-containing lysed cell bulk at pH 4.5 and pH 7.0 (the bulk used was not treated with
Benzonase® nor clarified in any way). Before adding the lysed cell bulk to the glass beakers
with the filter aids a sample was retrieved, the was measured (MM40+, CRISON, Spain) and
the turbidity was determined (2100Qis Portable Turbidometer, HACH®, Germany). The
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mixtures were incubated at 20-22¶C under constant and gentle stirring. After 30 min and
60 min of incubation the stirring was stopped (allowing the filter aid to settle by gravity) a
sample was collected.
Upon sample analysis the TP and IP recovery yield (YTP and YIP) were determined
accordingly with equation 2.1 and 2.2, respectively.
YVP =
CVPV
CVP,iVi
(2.1)
YIP =
CIPV
CIP,iVi
(2.2)
Impurity – i. e., DNA and HCP – clearance (%) were also assessed and calculated as
defined by equation 2.3 and 2.4, respectively.
DNA Clearance = 1 ≠ CDNAV
CDNA,iVi
(2.3)
HCP Clearance = 1 ≠ CHCPV
CHCP,iVi
(2.4)
2.5 Ultrafiltration studies
The ultrafiltration devices were kindly provided by Dr. Tobias Schleuss (Membrane R&D,
Sartorius Stedim Biotech, Germany). The membranes modules were set up accordingly with
the manufactures’ instructions. Briefly, a Tandem 1082 Pump (Sartorius Stedim Biotech,
Germany) was used to feed the clarified bulk to the membrane device, the retentate was
recycled to the feed container and the permeate was collected separately. The TMP (see
equation 2.5) was controlled by adjusting the retentate flow rate using a flow restriction
valve. Sartocon Slice 200 Filter Holder was used (#17525 --- 01, Sartorius Stedim Biotech,
Germany) for cassette devices. MasterFlex®14 tubing (MasterFlex Group, Germany) with
1.6 mm internal diameter was used. The pressure was monitored at feed inlet, retentate
outlet and permeate outlet by in-line pressure transducers (080-699PSX-5, SciLog®, USA).
Retentate temperature was measured with thermocouple sensor (56-4110-05 and PRT-DPM-
3T/50, GE Healthcare Life Sciences, Sweden). The feed/retentate and the permeate volumes
were monitored using a technical scale (TE4101, Sartorius Stedim Biotech, Germany).
TMP = Pf + Pr2 ≠ Pp (2.5)
Before any experiment the membranes were thoroughly rinsed with ultrapure water
(Grade 1, as defined in ISO 3696) to eliminate trace preservatives. Membrane permeabil-
ity was determined by the normalized water permeability corrected for 20¶C (NWP20¶C,
LMH bar-1 © L m-2 h-1 bar-1). The NWP20¶C (equation 2.6) was calculated based on pure
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water permeate fluxes (JP) measured at five di erent TMP between 0.4 and 2.0 bar.
NWP20¶C =
K
÷
= JpTMPTCF (2.6)
The NWP was corrected for 20¶C using the temperature correction factor (TCF, equa-
tion 2.7) based on water dynamic viscosity (÷) [128].
TCF = ÷T
¶C
÷20¶C
(2.7)
This measurement was done before the experiment, after the experiment and after CIP.
After conditioning the UF system with diafiltration bu er (20 mM TRIS, pH 8.0, 25 mM
NaCl), 450 mL of clarified feedstock containing Ad5 or RV were concentrated 10-fold and then
were diafiltered five times. The UF/DF test was performed at a constant pressure of 1.2 bar
and at a constant feed flow rate (cross-flow) equivalent to a linear velocity (v) of 0.202 m s-1
(see Table 2.1). For the RV ultrafiltration with Type H membrane it was not possible to
achieve the TMP of 1.2 bar while maintaining a recirculation flow rate appropriated for
TFF. Therefore, exceptionally in this case the performance test was run at a TMP of 0.9 bar.
The linear velocity used was kept constant for all experiments in order to have the same
tangential flow/force. Unless stated otherwise, the membranes used for RV were coated
before UF experiment with 40 mL of 4 g L-1 human serum albumin (HSA) prepareted in
bu er 1. The HSA was recirculated at 120 mL min-1 for 10 min.
Throughout the filtration process samples of the retentate were collected and stored at
-80¶C for further analysis.
The permeate flux was recorded by means of gravimetric control and membrane through-
put capacity – · , the amount of feed processed within a period of time (t) using a given
membrane area (A) – was determined according to equation 2.8.
· = Vi
At
(2.8)
Also the shear rate at the wall (“̇w) under laminar flow conditions (Reynolds number,
Re, < 2100 ) for HF and cassette modules were calculated as defined in equation 2.9 and
2.10 [129], respectively.
“̇w =
8v
d
= 4Q
nfir3
(2.9)
“̇w =
6v
h
= 6Q
wh2
(2.10)
The CIP procedure consisted of washing the UF system with 1 M NaOH at a flow rate of
500 mL/min and then a 60-min incubation. After this treatment the system was rinsed with
ultrapure water until the outlet stream reached pH 7.
For the Ad5 runs, all procedures were conducted at 20–22¶C, while fro RV runs all pro-
cedures were performed at 8–14¶C.
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2.6 Membrane chromatography
Membrane sheets and 96-well membrane holder were kindly provided by Dr. Louis Villain
(Membrane R&D, Sartorius Stedim Biotech, Germany). The membrane adsorbers func-
tionalized with a quaternary amine (Q) had three ligand densities and two di erent surface
structures, hydrogel-grafted and directly grafted (see Figure 2.1). The hydrogel-grafted mem-
(a) (b)
Figure 2.1: Schematic representation of the two membrane structures: (a) hydrogel-grafted membrane
where the Q ligand (red dots) is immobilized in the tentacle-like structure; and (b) directly grafted
membrane where the ligand is immobilized directly onto the membrane surface. Experimental design
space for the hydrogel-grafted membranes.
brane had ligand densities of 1.7, 2.4 and 3.3 µmol cm-2, while the directly grafted membrane
had 0.5, 2.5 and 4.5 µmol cm-2. The small-scale device had a bed volume of 23 µL and
500 µL of bu er or virus (clarified, concentrated and diafiltered by UF) were used. The chro-
matography consisted of three steps: equilibration; virus load, and elution. The equilibration
bu er was 50 mM HEPES, pH 7.5 with di erent NaCl concentrations (0, 50, 100, 150 and
200 mM). The virus feed was diluted 1:2 with concetrated bu er to match the conductivity
of the equilibration bu er. Elution was performed with 50 mM HEPES, pH 7.5, 1.0 M NaCl.
After depositing the equilibration bu er inside the wells a vacuum of 0.35 bar was applied
to displace the liquid across the membrane bed; the same procedure was applied for virus
load and elution steps. The scale-down chromatography was performed in duplicate and the
samples were stored at -80¶C until further analysis.
2.7 Analytical methods
2.7.1 Total virus particles quantification
Total virus particles concentration and size distribution were measured using the
NanoSIGHT NS500 (NanoSIGHT Ltd, UK). The samples were diluted in D-PBS (14190-
169, Gibco®, UK) so that virus concentration would be in the 10+8–10+9 particles mL-1 – the
instrument’s linear range. For each sample three 60-second videos were acquired and particles
between 70 and 130 nm were considered.
2.7.2 Infectious virus particles titration
The infectious virus assay for both Ad5 and RV is based on GFP transgene expression
upon infection (transfection) and flow citometry analysis.
For Ad5 titration, 293 cells were seeded at 0.25◊10+6 cell per well in 24-well flat bottom
plates (42475, Nunc, Denmark). After 24 h, the cells from three wells were trypsinized
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and the cell concentration was determined. The cell culture medium was removed from the
remaining wells and replaced with 1 mL of viral suspensions (10-1 - 10-6) diluted in fresh
medium. After 17 to 20 h, the cells were collected in Dulbecco’s phosphate-bu ered saline
(D-PBS, 14190-169, Gibco®, UK) with 5 % FBS and immediately analyzed by flow cytometry
(CyFlow®space, Partec GmbH, Germany) with GFP filters.
For RV titration, 293 T cells were seeded at 0.20◊10+6 cell per well in 24-well flat bottom
plates (42475, Nunc, Denmark). After 24 h, the cells from three wells were trypsinized and the
cell concentration was determined. The cell culture medium was removed from the remaining
wells and replaced with 200 µL of viral suspensions diluted (1/3–1/81) in fresh medium
supplemented with 8 µg mL-1 of polybrene (H9268, SIGMA-ALDRICH®, Switzerland). The
virus-containing medium was removed 4 h after infection and replaced with 800 µL of fresh
medium.
2.7.3 DNA quantification
Total DNA was quantified using the fluorescence-based Quant-iT™ PicoGreen® assay kit
(P7589, Invitrogen™, UK) according to manufacture’s protocol. In order to avoid matrix
interference, the samples were diluted between 2–256-fold with the provided reaction bu er.
The assay took place in a white 96-well microplate (437842, Nunc, Denmark) and the fluo-
rescence was measured on a Modulus™ Microplate Multimode Reader (Turner BioSystems,
now Promega, USA).
2.7.4 Protein analysis
Total protein was quantified using the BCA Protein Assay Kit (23225, Thermo Fisher Sci-
entific, USA) according with the manufacture’s protocol. Bovine serum albumin (BSA) was
used for the calibration curve. In order to avoid matrix interference, the samples were diluted
between 2- to 256-fold. The assay took place in a clear 96-well microplate (82.1581, Sarst-
edt, Germany) and the absorbance was measured on a SpectraMax 340PC384 Absorbance
Microplate Reader (Molecular Devices, USA).
Host cell protein was performed using the HEK 293 HCP ELISA Kit (F650, Cygnus
Technologies, USA) following the manufacture’s protocol. The standard curve was done
using the 293 HCP standards provided. 1/1 000, 1/5 000 and 1/10 000 in order to allow
interpolation. As suggested by the manufacturer the corrected absorbance (Abs) was used
(absorbance at 450 nm minus absorbance at 650 nm).
All analytical assays performed were done in triplicate.
The protein profile was analyzed by sodium dodecyl sulphate polyacrylamide gel elec-
trophoresis (SDS-PAGE). Pre-casted gels NuPAGE® 4-12% Bis-Tris (NP0321PK2, Novex®,
UK) were used. The samples were prepared by protein precipitation and ressuspension in
loading mix (prepared accordingly to the manufacture’s instructions) . The samples were pre-
cipitated by adding a known amount of protein to an eppendorf containing 1 mL of absolute
ethanol (4146052, Carlo Erba Reagents, Italy). After the protein precipitation overnight at
-20¶C the samples were centrifuged at 13 000 g for 15 min and the supernatant was removed.
The pellet samples were further dried by incubation at 37¶C and then resuspended in the
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loading mix. As molecular weight marker (MWM) 7 µL of SeaBlue Plus2 Pre-Stained Stan-
dard (LC5925, Novex®, UK) were loaded. The electrophoresis was performed at constant
voltage of 200 V for 35 min. The gel was stained with InstaBLUE™ (ISB1LUK, Expedeon,
UK) for 45 min under gently agitation and excess dye washed with ultrapure water. Digital
image was acquired with the ChemiDoc™ XRS+ (BIO-RAD, USA).
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3
Body Feed Filtration
The lysed bulk turbidity was determined to be 68±3 NTU (average±standard error of
the mean (SEM)) while wet cell weight (WCW) was 8±1 g L-1. The results presented below
are corrected in order to take into account a concentration factor since it was noticed that
the incubation volume – after adding the filter aid material – was reduced by 2–3-fold due to
material hydration (see Figure A1, in Appendix). The Figure A2 shows the wet filter aid with
50 mL of virus bulk after settling for 48 h; up to 70 % of liquid height is filled by the filter aid
material. This volumetric concentration is further supported by the analytical assays’ results
with virus recovery yields above 150 % and 2–3 times more DNA and HCP mass comparing
with the feed bulk (when 50 mL final volumes was considered). This concentration event
was also confirmed with the total protein quantification assay (data not shown). The specific
concentration factor was defined considering the filter aid and liquid supernatant height.
3.1 Virus recovery
The incubation assays at pH 4.5 resulted in TP recoveries bellow 2 % for the Celpure C300,
Celpure C1000 and Celite S filter aids. Moreover, the Celite S material also resulted in less
than 2 % recovery at pH 7.0. The filter aid/pH conditions with less than 2 % TP recovery
were readily excluded while the remaining were further analyzed.
The Divergan RS filter aid shown the highest TP recoveries (Figure 3.1) among the ma-
terials tested – approximately 40 % for the pH 7.0 condition. On the contrary, the Celite S
resulted in the worst performance regardless of incubation time or pH-value. Both Celpure
filter aids yielded TP recoveries ranging from 18 to 25 % at neutral pH. No di erences were
found in product recovery with increasing incubation time, except for the Divergan RS at
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Figure 3.1: TP recovery (average±SEM) after incubation during 30/60 minutes for the di erent filter
aids and pH conditions.
pH 4.5. Despite a decrease in Ad5 recovery was observed in this condition, careful inter-
pretation of this result is needed. As the pI of the Ad5 is approximately pH 4.5 [36] virus
aggregation and precipitation must be considered at this pH.
The IP data (Figure 3.2) confirmed the Divergan RS as the filter aid enabeling the highest
virus recovery. The Divergan RS material at pH 7.0 resulted in 39 % IP recovery after 30-min
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Figure 3.2: IP recovery (average±SEM) after incubation during 30/60 minutes for the di erent filter
aids and pH 7.0.
incubation while the Celpure C300 and C1000 recovered less than 25 % of the infective virus.
Contrarily to the TP data, there is a slight decrease in IP recovery with increasing incubation
time. Although Ad5 is considered a quite stable model virus [130,131], the mechanical stress
caused by mixing the filter aid micrometric particles for such a long period of time may be the
explanation for the results obtained. Especially, when considering the Ad structure where
the protuberant fiber protein – essential for cell adhesion and infection – is exposed more
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than 10 nm out of virus capsid [32].
3.2 Impurity removal
Concerning the DNA clearance (Figure 3.3), the incubation at neutral pH yielded lower
DNA clearance – between 15 and 54 % – comparing with the incubation at pH 4.5, which
enabled considerably higher DNA removal, close to 100 %. The enhanced DNA clearance
at pH 4.5 might be due to low pH-induced precipitation and aggregation with the virus
particles [72]. Celpure C300 showed the best DNA removal capacity at pH 7.0. Although
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Figure 3.3: DNA clearance (average±SEM) after incubation during 30/60 minutes for the di erent
filter aids and pH conditions.
this DE is a negatively charged material [132], other types of interactions – like entrapment,
flocculation or hydrophobic interaction – might be responsible for the high DNA clearance.
A similar phenomenon was observed recently in cation exchange (CEX) chromatography [133].
The publication reports the binding of DNA present in a post-Protein A mAb pool under
low conductivity (5 mS cm-1) and its elution upon a conductivity increase to 70 mS cm-1.
The Celpure C1000 is also negtively charged, however resulted in lower DNA clearance which
can be explained by the by the smaller specific area, up to 75 % less of the specific area of
Celpure C300 material [132]. Contrarily, the Divergan RS filter aid is not charged, even so it
led to DNA removal rates close to those of Celpure C300. The Divergan RS has a specific area
of ~55 m2 g-1 (estimated based on filter aid density and an average diameter of 90 µm [134]),
which is one order of magnitude higher as compared with the Celpure C300. Besides the
di erent – non-electrostatic – interaction mechanism, the high specific area of Divergan RS
might contribute also for the high DNA clearance.
Considering the HCP clearance (Figure 3.4), the results ranged from 50 to 80 %. Since
HCP is a complex array of proteins with di erent molecular size, charge, pI and stability, the
incubation at acidic pH did not provide substantial HCP clearance, contrary to what was
observed for DNA. Perhaps this is also why no remarkable di erence was observed between
both Celpure’s DE and the synthetic Divergan RS. Additionally, incubation for a long period
of time did not increase neither HCP nor DNA removal.
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Figure 3.4: HCP clearance (average±SEM) after incubation during 30/60 minutes for the di erent
filter aids and pH conditions.
3.3 Discussion
The Celite S material was readily excluded as no virus particles were recovered regardless
of incubation time or pH-value. On the contrary, the two other DE-based filter aids enabled
virus recoveries between 18 and 25 % when used at pH 7.0. The major di erence between the
Celite S and the Celpure materials lies in the SiO2 purity and metallic oxides content [132].
The Celite S material is a material less pure with a greater metal content when compared
with the Celpure DE. The DE purity seems to limit virus recovery and should be considered
when developing purification strategies such as the BFF.
Low virus recoveries were observed when the incubation was performed at pH 4.5, as
expected since the virus has a acidic pI. However, the results obtained show that the non-
charged material might be employed at acidic pH. This could be an advantage if a vaccination
application (which does not require infective virus) is envisioned, nevertheless pH and con-
ductivity should be further optimized for TP recovery and impurity removal.
The synthetic material Divergan RS resulted in the highest TP and IP recoveries while
maintaining HCP and DNA removal capacities comparable with the charged Celpure C300.
Even so the Divergan RS allowed for less than 50 % of product recovery. The low yields can
be explained by the small-scale set-up and protocol used. The experiment was focused on
filter aid screening therefore the Ad5 bulk was overloaded with DE to a final concentration
of 200 g L-1 – approximately 10-fold higher than those to be used in a scalable filtration
trial. While overloading is suitable for a initial material selection, it might lead to lower virus
recovery.
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Ultrafiltration
4.1 R&D prototypes
4.1.1 Hydraulic permeability
All eight UF prototypes were characterized and the NWP20¶C is reported in Figure 4.1.
The two PES cassettes registered the highest NWP20¶C, up to 924 LMH bar-1, which may
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Figure 4.1: NWP20¶C (average±standard error of the mean (SEM)) for the di erent R&D UF proto-
types provided.
be explained due to the high MWCO. Both RC cassettes exhibited NWP20¶C close to
560 LMH bar-1 whereas the mRC permeability only reached 400 LMH bar-1, probably due to
di erent construction material and/or manufacture (e. g. flow channel height). Regarding
the HF, these modules shown lower permeability when compared with the PES cassettes and
some of the RC-based cassettes. As expected the lower MWCO displayed lower permeability
than the HF of higher MWCO, since their features are identical (number of fibers per module,
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fibers’ internal diameter and membrane material).
4.1.2 Virus recovery
Samples were collected during the UF when 3, 5 and 10 concentration factors (CF) were
achieved and also after 2 and 5 diafiltrations (DF). The samples were further analyzed to
determine the filtration performance of each UF device. The Figure 4.2 and Table 4.1 show
the TP and IP recovery, respectively.
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Figure 4.2: Total virus particles recovery (average±SEM) as function of concentration fac-
tor/diafiltration volume for the di erent R&D UF prototypes.
All RC-based cassettes were capable of the high TP recoveries, ranging from 69 up to 93 %
after 2 DF. Contrarily, the PES-based membranes allowed for virus permeation as shown by
the low TP recovery (23–58 %). In part this was expected, since the PES cassettes have the
highest MWCO.
The IP data presented in Table 4.1 is in agreement with the TP recovery. All the RC-
Table 4.1: IP recovery and processing time for 10-fold concentration for the di erent R&D UF proto-
types.
Module Material Prototype IP recovery
(%±SEM)
Processing
time (min)
Shear rate
(s-1)
Cassette
RC Type B 94±14 14
3186Type C 85±11 30
mRC Type D 79±11 24Type E 103±13 14
PES Type #2 89±16 19 4037Type #4 54±11 17
Hollow PES HF 3 60±4 105 1613fiber HF 5 8±2 48
based cassettes were able to recover between 79 and 100 % of infective virus particles at the
end of the concentration step. Interestingly, between these four modules, the ones with larger
MWCO were the ones with higher IP recoveries, close to 100 %. This result points towards
the importance of optimizing the choice of cassette and MWCO for the lowest processing
time to avoid loss of infectivity due to shear-induced damage.
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Following the same trend observed in TP recovery, the Type #2 cassette allowed for a
higher IP recovery as compared with the PES #4 module. These PES cassettes have the
same membrane material and the same MWCO; however, slight di erences, such as a broader
(or narrower) pore size distribution, could impact the prototype’s virus recovery [84].
The HF prototypes had low recovery of IP. This can be explained by the longer processing
times. For instance, the HF 3 module took seven times longer than the Type B or Type E
prototypes to perform the same 10-fold concentration. Even so, the HF 3 showed a moderate
IP recovery (60±4 %).
4.1.3 Impurity removal
4.1.3.1 Protein clearance
The HCP analysis presented in Figure 4.3 shows that both PES cassettes were able
to remove 86–91 % of the HCP present, as expected due to high MWCO. The remaining
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Figure 4.3: HCP clearance (average±SEM) after 2 diafiltrations for the di erent R&D UF prototypes.
prototypes were able to remove between 70 and 80 % of HCP, in agreement with the literature
of UF step [72,95].
All four RC-based UF membranes show a marked enrichment in Ad5 protein bands as
compared with the feed in the SDS-PAGE (Figure 4.4), in agreement with the high TP and IP
recovery yields. This is specially visible with the virus’ major capsid protein (hexon, 109 kDa)
and resulted from the successful volumetric concentration and virus retention. Also, the PES
hollow fibers led enrichment in hexon protein, however not as much as the RC-based modules.
Furthermore, as demonstrated by TP recovery, the PES cassettes tend to retain less virus
due to their high MWCO.
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Figure 4.4: Total protein profile analyzed by SDS-PAGE after 2 DF in comparison with the feed and
a CsCl ultracentrifugation-purified Ad5 standard. Each well was loaded with 15 µg of total protein.
4.1.3.2 DNA clearance
Both PES-based cassettes enabled higher DNA clearance – 85% – than the remaining
prototypes (Figure 4.5). The Type B, Type C, Type D, Type E and HF 5 prototypes shown
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Figure 4.5: DNA clearance (average±SEM) as function of concentration factor/diafiltration volume
for the di erent R&D UF prototypes.
intermediate DNA clearances (67–70%) and the HF 3 shown the worst DNA clearance (61 %).
Both the HCP and DNA clearance data are in agreement and point out both PES cassettes
as the best modules regarding impurity removal. However, considering also TP and IP data,
these modules were not as e cient as the RC-based membranes.
4.1.4 Productivity analysis
The permeate flux over time and throughput (feed processed per membrane area and
time, L m-2 h-1) were also evaluated for all UF prototypes studied (Figure 4.6).
The Figure 4.6(a) shows that all membranes except Type D were able to maintain an
essentially stable flux, due to the TMP-constant operation. On the other hand the Type D
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Figure 4.6: (a) Permeate flux throughout filtration and (b) throughput capacity for each R&D UF
prototype assayed (considering a 10-fold concentration and 2 DF).
shown a marked flux decrease between 300 to 405 mL of permeate volume (between 3 to
10 CF). However, complete fouling was not observed. It is also important to point out that
the two UF modules which displayed superior throughput (Figure 4.6(b)) – RC Type B and
mRC Type E – were also the ones showing highest virus recoveries. This combination makes
them modules of high productivity (product recovered per membrane area and time).
4.1.5 Flux Recovery
The after-use flux recovery enables assessment of the degree of irreversible/strongly as-
sociated foulants accumulated on the membrane during filtration. On the other hand, the
after-CIP flux recovery permits to evaluate the loss of permeability after a complete cy-
cle. This metric is an industrial relevant indicator as it serves as benchmark of membrane
performance, is used to assess performance decay and also cleaning-in-place (CIP) protocol
e ectiveness. The flux recoveries (flux over initial flux, J/J0 (–)) are presented in Figure 4.7.
Three membranes (Type B, Type D and Type E) have shown a reduced fouling compared
to the others. These results can be related, in part, with di erent hydrophilic properties
of the membranes’ material. In contrast, RC Type C was not able to recover to its initial
flux to the same extent as the Type B, possibly due to the lower MWCO. All PES-based
prototypes had low after-use flux recovery. Considering the wide range of MWCO of these
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Figure 4.7: Flux recovery (average±SEM) after-use and after-CIP for the di erent R&D UF prototypes
prototypes, the results suggest that PES UF membranes might be more prone to adsorbing
biomolecules [74,90].
Regarding the after-CIP flux recovery, it was clear that the PES cassettes, the Type B
and both mRC cassettes regained their permeability (with flux losses ranging between 7 and
11%). Meaning that these UF modules withstood a complete cycle and might be used as a
repeated-use device; although the number of cycles allowed was not assessed. The remaining
modules (RC Type C and both PES hollow fibers) shown loss of water permeability after one
cycle, and might not be suited for repeated-use device.
4.2 Commercial/pilot production devices
The results obtained with R&D UF prototypes were used to adjust the membrane features.
A new set of improved UF membranes produced by a fully scalable manufacturing line was
evaluated for Ad5 and RV ultrafiltration.
4.2.1 Hydraulic permeability
The mRC Type H cassette displayed the highest NWP20¶C – 889 LMH bar-1, Figure 4.8 –
possibly due to the high MWCO. As expected the Type F cassette shown lower NWP20¶C
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Figure 4.8: NWP20¶C (average±SEM) for the di erent UF devices studied.
– 739 LMH bar-1. The NWP20¶C for the HF 7 was determined to be 630 LMH/bar. The
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lower permeability of the HF 7 comparing with the same cut-o  cassette might be explained
by di erences in membrane material and/or module design.
4.2.2 Virus recovery
Samples were collected during the UF when 3, 5 and 10 concentration factors (CF) were
achieved and also after 2 and 5 diafiltrations (DF). The samples were further analyzed to
determine the filtration performance of each UF device.
The Ad5 experiments resulted in TP recoveries ranging from 50 % (Type H) up to 75 %
(Type F) after 10-fold concentration (Figure 4.9); however two diafiltration (DF) volumes
decreased the recovery yield to 40 % for all membranes assayed.
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Figure 4.9: Total virus particles recovery (average±SEM) as function of concentration fac-
tor/diafiltration volume for the di erent UF devices.
The RV experiments yielded lower recoveries for all UF devices; Type F (lower MWCO)
membrane had the higher TP recovery of 48 %. The remaining membranes were only able to
recover between 8 and 14 % of RV particles. It has been suggested that coating membrane
filters with HSA leads to lower RV loses [83,93], however in this case the HSA coating did not
increase RV recovery when the PS HF was tested.
The IP data (Table 4.2) shows the same trends observed in TP recovery for both Ad5
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and RV.
Table 4.2: IP recovery and processing time for 10-fold concentration for the di erent UF devices.
Virus Module Material Device
IP recovery
(%±SEM)
Processing
time (min)
Shear rate
(s-1)
Ad5
Cassette mRC
Type F 124.9±12 17.5
3186
Type H 93.6±16 17.2
Hollow Fiber PS HF 7 111.7±13 26.4 1619
RV
Cassette mRC
Type F 8.9±1 4.4
3186
Type H 13.5±3 3.8
Hollow Fiber PS
HF 7 15.3±3 3.3
1619
HF 7 † 15.9±1 3.8
†The UF membrane was not coated with HSA (see Section 2.5, page 20).
The Type F and HF 7 membranes were able to fully recover the infective Ad5 while Type H
membrane achieved 94 % recovery. As observed for TP recovery, Type H resulted in the
lowest recovery, possibly due to its high MWCO. Despite being rated with the same MWCO
as the Type H cassette, the HF 7 was able to recover more infective Ad5, which could be
explained by the lower shear rates associated with its operation.
As observed previously, the low RV recoveries were also confirmed by the low IP recoveries,
between 9 and 16 %. The only exception was the Type F membrane whose discrepancy
between TP and IP data suggests that virus functionality was lost, possibly due to shear-
induced damage.
4.2.3 Impurity removal
4.2.3.1 Protein clearance
The mRC Type F and Type H cassettes removed 67 and 68 % of HCP, respectively, while
the PS-based HF 7 was able to achieve 86 % HCP clearance (Figure 4.10). The higher HCP
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Figure 4.10: HCP clearance (average±SEM) after 2 diafiltrations for the di erent UF devices.
protein clearance registered for the HF might be due to the di erent filter material, which
is more hydrophobic than RC, and thus more prone to adsorption. The protein clearance
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obtained is in agreement with the available data for the UF step [72,95].
For the RV runs the HCP clearance was higher compared with those obtained for Ad5;
in this case 83, 94 and 99 % HCP was obtained for Type F, Type H and HF 7, respectively.
These values are slightly higher comparing with has been reported for RV UF [83,135], with
protein clearance rates in the 70–80 % range. The higher protein clearances for the RV runs
were expected since no cell lysis step was performed and thus the RV feed contains essentially
small proteins present at low concentrations in cell culture supernatant.
The protein profile (Figure 4.11) regarding the Ad5 experiments shows a clear enrichment
in Ad5 proteins’ compared with the feed, which is in agreement with the high virus recoveries
registered. The volumetric concentration is particularly evident on the adenovirus’ major
capsid protein band (Hexon, 109 kDa). With the RV UF it is also possible to observe
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Figure 4.11: Total protein profile analyzed by SDS-PAGE after 2 diafiltration volumes in comparison
with the feed. The left gel concerns the Ad5 runs and a CsCl ultracentrifugation-purified Ad5 standard,
whereas the right gel corresponds to the RV experiments. Each well was loaded with 15 µg of total
protein.
the concentration and retention of retroviral particles, particularly on the virus’ envelop
glycoprotein (Env, 70 kDa) which is enriched comparing with the feed. The slight enrichment
is in accordance with the low recoveries obtained; however it is not possible to distinguish
between the di erent membranes.
4.2.3.2 DNA clearance
The DNA analysis performed (Figure 4.12) reveled that lower DNA removal was achieved
in Ad5 runs compared with RV experiments. One of the challenges of Adenovirus purification
is host cell DNA removal since the bioprocess comprises a cell lysis step [136] but also because
it has been shown that DNA can associate with the virus particle resulting in co-purification
of both species [72]. For the Type F and Type H cassettes the DNA clearance after two DF
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Figure 4.12: DNA clearance (average±SEM) as function of concentration factor/diafiltration volume
for the di erent UF devices.
was 64 and 60 %, respectively, while the HF 7 was able to remove 82 % of DNA present in the
Ad5 feed. In the range of MWCO assayed, there was no observed di erence between medium
and high MWCO cassettes, therefore the higher HCP and DNA clearance observed with
PS-based HF 7 membrane might be due to adsorption. Considering the RV experiments, the
Type H and HF 7 removed 95 and 98 % of the DNA present, respectively, while the Type F
membrane enabled slightly lower DNA clearance (86 %).
4.2.4 Productivity analysis
As with the previous set of membranes, the permeate flux over time and throughput (feed
processed per membrane area and time) were evaluated for all UF devices (Figure 4.13). The
Figure 4.13(a) shows that all membranes were able to maintain an essentially stable flux
during the TMP-constant operation, and no device shows signs of fouling. It is also important
to point out that the higher permeate fluxes achieved for RV are consequence of the clearer
starting material, as stated earlier.
When the UF devices were challenged with the Ad5 clarified bulk it is evident the higher
throughput of the mRC-based membranes compared with the PS-based HF 7 (Figure 4.13(b)).
Particularly, the Type F membrane – which combines high throughput capacity with the high-
est TP and IP recoveries – is a high productivity module (product recovered per membrane
area and time). However, when the clearer RV-containing supernatant was used the advan-
tages of module design and filter material are no longer evident. In this case throughput
capacity displayed a similar trend, related to the hydraulic permeability (Figure 4.8).
4.2.5 Flux Recovery
The after-use flux recovery enables assessment of the degree of irreversibly/strongly asso-
ciated foulants accumulated on the membrane during filtration. The after-CIP flux recovery
permits to evaluate the loss (or gain) of hydraulic permeability after a complete cycle. The
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Figure 4.13: (a) Permeate flux throughout filtration and (b) throughput capacity for each UF device
assayed (considering a 10-fold concentration and 2 DF).
flux recoveries (J/J0) are presented in Figure 4.14.
The two mRC cassettes have shown a reduced fouling compared with the PS hollow fiber
(HF 7) in both Ad5 and RV trials. This fouling is particularly evident when Ad5 is used,
resulting in flux recovery of 24 % for the HF 7 while the cassettes were able to recovery up
to 58 % of the initial flux. The results suggest that the PS-based UF devices might be more
prone to fouling through adsorption of biomolecules.
After CIP, both the mRC cassettes fully recovered their permeability (96 and 97 % flux
recovery). This provides a good indication for membrane as a reusable device. Contrarily,
the HF 7 shows performance decay after CIP, since its hydraulic permeability was increased
by 17 % after the CIP protocol recommended by the manufacturer. A unstable membrane
could then be responsible for changes in the product and/or impurities retention rate.
4.3 Discussion
R&D UF prototypes
Concerning the R&D prototypes (reported in the first part of this chapter), the PES
hollow fiber modules have shown the worst performance under the conditions evaluated.
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Figure 4.14: Flux recovery (average±SEM) of the di erent UF devices evaluated after-use for Ad5
and RV runs and after-CIP for the Ad5 run
This is supported by the lower IP recoveries and longer processing times. While the HF 5
lost nearly all virus, the HF 3 was still able to recover 60% of IP but the long processing time
is a considerable disadvantage. The results obtained by the PES R&D prototypes, namely
virus recovery, are bellow what has been described in the literature for this MWCO range.
For instance, 300 kDa HFs from GE was able to concentrate an Ad5 bulk 10-fold with 96 % IP
yield [66]. In another report [97], a 300 kDa HF (GE) and 400 kDa HF (Spectrum Laboratories)
were used enabling Ad5 recoveries of 83 and 100 %, respectively.
The RC-based R&D prototypes have shown better performances, especially concerning
VP and IP recovery. The Type B and Type E membranes registered similar or even better
virus recovery yields than what has been reported for Ad5 ultrafiltration [66,95,97]. The RC
Type B and mRC Type E have shown minimal IP loss, with IP recoveries above 94%, meaning
that shear rates used are not damaging for this product. These membranes displayed similar
HCP clearance (68 and 71%) and DNA clearance (67 and 70%, respectively) [72,95,135]. These
two modules also possessed high throughput capacities, being able to process up to 77 L of
feed within 1 hour using 1 m2 ultrafiltration module. (The throughput analysis was done
considering a 10-fold concentration and 2 bu er exchanges.) Considering the unit operation
and early stage in downstream processing train, high recovery yields and high throughput
capacities are preferred over high impurity removal rates.
Commercial/pilot production UF devices
Considering the commercial/pilot production UF devices (presented in the last part of
this chapter), the Type H membrane (high MWCO) has shown high virus recovery yield and
was able to recover up to 97 % of infective Ad5, which is an improvement compared with
the recovery described in the literature for a similar MWCO HF [66]. Despite the promising
results with the Ad5, similar results were not achieved for the RV. Protein and DNA removal
rates were close to what was observed with the other UF membranes and are in agreement
with what has been reported for both Ad5 and RV ultrafiltration steps [72,95,135].
The HF 7 was also capable of delivering high Ad5 recovery, with full IP recovery. However
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as observed for the Type H cassette, the HF with the same MWCO was not capable of RV
concentration, resulting in low yields. Considering impurity removals, the PS HF seems to
enable slightly increased DNA and HCP clearance comparing with mRC cassettes; this was
more evident with the Ad5 bulk. This increased impurity removal might be due to adsorption
phenomenon rather than a size exclusion mechanism as the filter material’s proprieties are
more hydrophobic [74,90].
The Type F cassette presented the best results among the assayed membranes. This is
supported by the complete recovery of infective Ad5, an improvement comparing with what
is described in the literature for 500 kDa HF [66]. Additionally, this was the only device able
to partially retain and concentrate RV. Although the Type F module was able to concentrate
RV, the low IP yield suggests that shear-induced damage might be compromising infective
RV recovery. The results indicated that lower MWCO did not decrease impurity removal
when comparing between the two mRC cassettes.
Another important feature of the Type F (and H) cassette(s) is their higher throughput
comparing with the HF 7. For instance, Type F module is capable of processing up to 61 L
of Ad5 clarified bulk within 1 h using a 1 m2-membrane while the GE HF can process only
29 L with the same time and membrane area (considering a 10-fold concentration and 2 DF).
Although the Type F throughput is 20 % lower compared with those obtained for the best
R&D prototype previously evaluated, careful comparison of such values is required since the
previous membranes’ MWCO might be slightly di erent and the manufacturing process was
di erent.
Retrovirus purification is extremely challenging due to the labile nature of the virus
particle and low titers achievable. The results achieved for Type F membrane – concentration
of TP without the corresponding increase in IP titer – suggest that there is loss of virus
functionality possibly due to shear-induced damage. One possible improvement would be
to decrease the shear rate by lowering the feed flow rate (and consequently the TMP in
order to maintain a tangential flow at the membrane’s surface). The literature is scarce on
purification of RV by UF [83,93,135,137], however careful examination allows to identify two other
explanation the low RV observed. First, MWCO in the 100–500 kDa range are preferred for
RV concentration, as observed in this study and supported by the literature [83,135]. Second,
the use of high membrane loads (feed volume per membrane area) might also be advantageous
given the low titers characteristic of RV. The same manuscripts [83,135] report membrane loads
ranging from 73 up to 133 L m-2 while in our trials membrane loading was limited to 22.5
and 20 L m-2 for the cassettes and HF, respectively. These three factors – shear rate, MWCO
and membrane load – might explain, at least partially, the low RV recoveries achieved.
The work performed characterized in-depth several ultrafiltration membranes. The results
herein presented identify UF membrane modules alternative to the currently available HF
devices for virus purification. Type F (close to 500 kDa) is suggested for Ad5 concentration.
This module shows complete IP recovery and impurity removal similar to those described in
the literature. The key advantage of this UF module lies in the substantially shorter pro-
cessing times comparing with the other membranes evaluated and described in the literature.
Considering the RV, several improvement strategies were suggested based on successful RV
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UF reports available in the literature.
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Membrane chromatography
adapted from:
Nestola, P., Villain, L., Peixoto, C., Martins, D.L., Alves, P.M.,
Carrondo, M.J.T., Mota, J.P.. Impact of grafting on the design of new
membrane adsorbers for virus purification. Biotechnol Bioeng, submitted.
The membrane adsorbers functionalized with a quaternary amine (Q) had three ligand
densities and two di erent surface structures (hydrogel-grafted and directly grafted). A
96-well chromatographic system was used to evaluate the impact of these features on the
membrane performance.
5.1 Hydrogel-grafted membranes
5.1.1 Virus recovery
Analysis of the flow-through detected less than 5 % of the loaded virus which is in agree-
ment with other reports where adenovirus are generally purified in bind/elute mode using
Q-AEX chromatography with hydrogel-grafted membranes [67,80].
Considering the virus recovery after elution with 1 M NaCl, the data displayed in Fig-
ure 5.1 show that low conductivity during loading results in recovery yields below 50 %
regardless of the ligand density. The high ligand density adsorber (3.3 µmol cm-2) resulted in
the lowest virus recoveries, as observed previously with Baculovirus [119]. The use of medium
ligand density membrane (2.4 µmol cm-2) resulted in the highest recovery yields ranging
from 50 % to 80 %. These recovery yields are in agrrement with what was published for
chromatographic purification of Ad5 using Sartobind Q [66].
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Figure 5.1: TP recovery after elution with 1 M NaCl for the hydrogel-grafted membrane with low,
medium and high ligand density.
Ligand density has also been studied for mAb chromatography, were increased ligand
density did not led to improvements in binding capacity and recovery [138]. Therefore, it
has been suggested that there is threshold level above which ligand density does not improve
matrix capacity [119,138]. However, the results herein presented show that increasing the ligand
density above a certain threshold level not only did not increase virus recovery but also had
a negative impact on virus recovery. This might be explained due to multi-point adsorption
– leading to a stronger association between the virus and the membrane – or due to virus
entrapment since, hydrogel layer thickness was increased in the highest ligand densities.
5.1.2 Impurity removal
5.1.2.1 Protein clearance
The total protein clearance obtained in the elution showed slight increase with increased
ionic strength. As expected, by increasing NaCl concentration of the load was possible to
increase protein clearance for mediun and high ligand densities (Figure 5.2). Also, the protein
clearance increased concomitantly with increases in ligand density. The low protein clearance
observed in the low ligand density (1.7 µmol cm-2) might be due to co-elution of proteins
with the virus during the elution with 1 M NaCl. This problem can be addressed by the
implementation of a gradient elution to improve resolution [119].
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Figure 5.2: Protein clearance after elution with 1 M NaCl for the hydrogel-grafted membrane with
low, medium and high ligand density.
5.1.2.2 DNA clearance
DNA is an impurity whose removal poses some challenges because of its high a nity to
the matrix; moreover, it can interact with the viruses. Considering the DNA clearance, no
di erence was observed between the di erent ligand densities assessed (Figure 5.3). Contrar-
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Figure 5.3: DNA clearance after elution with 1 M NaCl for the hydrogel-grafted membrane with low,
medium and high ligand density.
ily, there was a notable increase in DNA clearance with increasing NaCl concentration in the
0–150 mM range. This suggests that increasing NaCl concentration in the load promotes
DNA removal in the flow-through fraction. (The strongly associated DNA associated with
the membrane was evaluated with 2 M NaCl elution and was found to be less than 7 %,
data not shown.) This conductivity-dependent binding capacity is a well-know e ect in AEX
adsorption: at the solid-liquid interface the charged surface attracts counter-ions from the
solution to form a "double layer" whose thickness is reduced with increasing ionic strength.
A thin double layer reduces the biomolecule’s contact area and thereby weakens and limits
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the electrostatic interactions between the ion exchange group and the biomolecule resulting
in reduced adsorption capacity [139,140].
5.2 Directly grafted membranes
5.2.1 Virus recovery
With the directly grafted membrane virus binding was heavily reduced as can be observed
by the high virus recovery in the flow-through and residual amounts eluted with 1 M NaCl
(Figure 5.4). This is the opposite of what was observed in the hydrogel-grafet membranes,
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Figure 5.4: TP recovery (a) in the flow-though and (b) after elution with 1 M NaCl for the directly
grafted membrane with low, medium and high ligand density.
despite the comparable ligand densities. As discussed previously, low conductivity promotes
biomolecule binding leading to virus recovery in the flow-through between 23 and 66 %
without NaCl. When the NaCl was increased to 50–100 mM the virus recovery was improved
up to 100 % for the medium ligand density (2.5 µmol cm-2).
Furthermore, in the experiments with the directly grafted membranes there was a good
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agreement between the viruses in the flow-through and in the subsequent elution, corrobo-
rating the hypothesis that incomplete virus recovery in high ligand density is related with
the hydrogel layer.
5.2.2 Impurity removal
5.2.2.1 Protein clearance
The analysis of total protein concentration in the flow-through did not show major dif-
ferences between the 0.5 and 2.5 µmol cm-2 ligand densities (Figure 5.5). The high ligand
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Figure 5.5: Protein clearance after elution with 1 M NaCl for the directly grafted membrane with low,
medium and high ligand density.
density (4.5 µmol cm-2) resulted in protein clearance slightly higher compared with the low
and medium ligand densities assayed, suggesting an increase in protein binding capacity due
to ligand density increase.
5.2.2.2 DNA clearance
In line with the results of HCP removal, loading with low conductivity resulted in higher
DNA binding (and removal from flow-through) when compared with 50 and 100 mM of NaCl
(Figure 5.6). The high and medium ligand density membranes seem to be more responsive
to NaCl concentration. When using these membranes, conductivity increases led to lower
DNA clearance in the flow-through faction, meaning a decreased DNA binding (as observed
previously, Figure 5.4). On the contrary, the low ligand density membrane shown a constant
DNA clearance (56–58 %) within the NaCl concentration range tested.
Comparing the DNA clearance for both types of membrane structure, the results show
that the hydrogel layer decrease accessibility of the DNA, resulting in high amounts of DNA
in flow-through. Whereas the directly grafted membrane enabled DNA binding as proved by
the 56–84 % DNA clearance in flow-though.
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Figure 5.6: DNA clearance in the flow-through for the directly grafted membrane with low, medium
and high ligand density.
5.3 Discussion
The membrane adsorbers were evaluated in bind/elute as well as flowthrough mode for pu-
rification of Ad5 from its process-derived impurities, such as DNA and total protein. A com-
plex feed stock derived from bioreactor production was used in order to obtain a more realistic
approach compared to other studies were model proteins or pure products are used [138,141].
In addition, the use of scale-down devices, such as the 96-well chromatographic system allows
to screen several factors while characterizing the design space (Figure 5.7)
(a) (b)
Figure 5.7: Experimental design space for the hydrogel-grafted membranes. The panel shows the (a)
recovery yield and (b) DNA clearance of the 1 M NaCl eluion for the hydrogel grafted membrane. A
decreased ligand density and increased ionic strength to value of 150 mM NaCl are suitable conditions
for hydrogel-grafted membranes.
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The hydrogel-grafted membranes yield higher virus recoveries than the directly grafted
membranes. Among the hydrogel-grafted membranes, lower and medium ligand densities
improve the performance of the purification process. Particularly, the medium ligand density
(2.4 µmol cm-2) appears to provide a good comprise between recovery yield (up to 85 %) and
impurity removal (up to 96 % of DNA clearance).
The directly grafted membranes shown low virus binding leading to significant percent-
ages of viruses in the flow-through, up to 100 %. Contrarily to the observed with the virus,
the absence of hydrogel layer resulted in increased DNA binding and removal from the flow-
through. Therefore, further improvements of these kind of membrane (for instance, by in-
creasing ligand density) might lead to enhanced DNA removal and optimization of directly
grafted membranes for polishing (flow-through) application.
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6
General Discussion and Conclusion
Viruses and VLPs play an important role in the current medical therapies and have an
enormous potential for the development of new applications in the fields of vaccination and
gene therapy. However, the success of complex biopharmaceuticals deeply depends on the
developers/manufacturers’ capacity to deliver clinical-grade lots with a cost-e ective manu-
facturing process. It must also guarantee a scalable and robust production delivering consis-
tently the required product quality, safety and purity.
relies greatly on the manufacturing process. This process must guarantee a scalable and
cost-e ective production while achieving consistently the demanded product purity, safety
and quality.
The upstream process has evolved substantially over the last few decades, on the op-
posite the downstream processing has been repeatedly identified as the bottleneck in the
biopharmaceutical process [7,142]. Recent e orts have been made in order to improve the
downstream processing, but its majority focused on the chromatographic separation with
innovative supports [67,115], column designs [120,121], ligands [143] and operation modes [63,122].
This work illustrated how new and unexplored technologies can improve the productivity
and e ciency of the entire DSP.
6.1 Debottlenecking the DSP rigth from the beginning
The upstream technology advances enabled high cell densities as part of process intensi-
fication e orts, however this and other improvements have created new challenges for bulk
clarification [19,23]. In addition to the high biomass content, the large volumes must be pro-
cessed quickly, especially when labile products are considered. The body feed filtration here
evaluated is suggested as an alternative for bulk clarification (Chapter 3). The filter aid
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trial enabled to select Divergan RS due to its superior Ad5 recovery. It is suggested that
the non-charged nature of this synthetic polymer combined with its high specific area are
responsible for the superior performance compared with the remaining DE assessed. Further
developments and integration into a scalable filtration set-up will render body feed filtration
as an alternative to depth filter clarification [77,82].
Ultrafiltration is a unit operation widely used in pilot- and industrial-scale purification
schemes [19,22,106]. Ultrafiltration can be applied to concentrate a bulk and/or to exchange
bu er in a scalable manner. The majority of the literature reports the use of HF modules
which are associated with lower shear rates but longer processing times when compared with
the flat-sheet cassette modules. In this work several cassette and HF modules were compared
for Ad5 and RV concentration and bu er exchange (Chapter 4). Our results indicate that
large cut-o  cassette modules are a suitable to Ad5 concentration with complete IP recoveries
in shorter processing times compared with currently available hollow fibers.
Chromatography, especially IEX chromatography, is a well-established operation for virus
purification due to it separation power and versatility [7,68]. Traditionally chromatography has
been performed with packed-bed columns, however new stationary phases, such as membrane
adsorbers, have several advantages capable of improving chromatography productivity by de-
creasing processing times and bu er usage. Furthermore, the low production cost enables the
use of membrane adsorbers as single-use devices, avoiding regeneration, CIP and validation
procedures. The work developed in this thesis demonstrates how specific membrane fea-
tures (i. e. ligand density and membrane structure) together with load conductivity impact
binding and purification of a Adenovrius model (Chapter 5). Our results demonstrate that
grafted membrane with a ligand density of 2.4 µmol cm-2 provided the best trade-o  between
high virus recovery and high DNA removal, when operated in bind/elute mode. In addition,
the use of a 96-well system enabled a high-throughput screening in a Design of Experiments
(DoE) approach.
6.2 Future work and outlook
This thesis’ work led to the identification of innovative technologies capable of improving
the current viruses DSP, however further optimizations are required. The body feed filtra-
tion should be implemented in a scalable set-up in order to confirm this novel technology
as an alternative for clarification. Further developments should target the characterization
of the intrinsic filter aid material permeability (with pure water), conductivity adjustments
and addition of floculants (domiphen bromide) or precipitants (e. g. (NH4)3SO4) to increase
filtration performance. Additionally, the determination of particle size, size distribution and
’–potential of the filter aid material (and virus bulk) would provide valuable information to
understand the interaction mechanism. Ultrafiltration using large MWCO cassette modules
was successfully employed to concentrate Ad5, but the low recoveries observed for RV indi-
cate that further optimizations are needed specially for low-titer and shear-sensitive viruses.
The following work should target the optimization of MWCO, shear rate and membrane load.
Also, it should be determined if increasing diafiltration bu er enables to increase the recovery
yield of this step. Considering the membrane adsorbers used for IEX chromatography, the
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determination of the dynamic binding capacity for viruses as well as for the main impurities
would be a valuable information towards a rational process development of the chromato-
graphic step. Such information could be later incorporated in the design of continuous or
semi-continuous chromatography operation.
The ultimate goal for DSP is to have a robust purification platform running continuously
delivering the required purity. Considering this goal, disposable devices (depth filters or ul-
trafiltration devices) will be helpful in early steps of the DSP [60,62], however chromatographic
separation still needs further development. In this context, continuous or semi-continuous
chromatography routines that have been suggested for mAbs might be applied also for virus
purification [63,144,145]. Besides continuous operation, convective mass transport chromato-
graphic supports like membrane adsorbers and monoliths can further enhance the produc-
tivity of chromatography [114,115]. Combination of these established technologies with old
separation technologies, such as precipitation and aqueous two-phase systems, could render
new and improved DSP schemes; however the feasibility of such revisited technologies must
be confirmed specifically for virus purification [100,103,116,146].
Following the Quality by Design (QbD) initiative launched by the FDA and Interna-
tional Conference on Harmonization (ICH) [147], scale-down tools that enable knowledge-
based process development [148,149] and improved analytical assays will be increasingly im-
portant [150–153].
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Appendix

Figure A1: Amount of the di erent filter aids used in dry state.
Figure A2: Volume filled by the wet filter aid with 50 mL of virus bulk after settling for 48 hours.
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